Zygolide brings the first FDA-approved generic pergolide for PPID
CURRENT BRIEF VERSION: Dechra’s Zygolide, a pergolide tablet for horses with pituitary pars intermedia dysfunction (PPID, or equine Cushing’s disease), is now entering the U.S. market as the first FDA-approved generic to Prascend. The FDA announced the approval on January 9, 2026, after determining Zygolide is bioequivalent to Prascend, and the agency’s approval summary shows the product was formally approved on December 19, 2025. The product is positioned around practical administration features, including a peppermint-flavored formulation and a scored tablet design highlighted in promotional materials carried by The Horse. Dechra’s campaign also leans into owner-facing quality-of-life language such as “Rediscover the partnership with Zygolide” and “Help your horse feel their best,” while describing the drug as a “cost-effective treatment” in advertising. (fda.gov)
Why it matters: For equine veterinarians, the biggest change is category-level competition in a long-established PPID treatment space. Pergolide remains the standard drug therapy recommended in consensus guidance, typically starting at 2 mcg/kg once daily, with label dosing not to exceed 4 mcg/kg daily. A generic entrant could improve access for some pet parents managing a chronic disease that often requires lifelong medication, dose adjustments, endocrine monitoring, and attention to adverse effects such as inappetence. That possibility is reinforced by Dechra’s own marketing emphasis on affordability, though real-world savings will depend on channel pricing and availability. The label also reinforces handling precautions, including avoiding crushing tablets because of human exposure risk. (static1.squarespace.com)
What to watch: Watch for how quickly Zygolide gains distribution, whether pricing meaningfully shifts PPID treatment costs in practice, and how veterinarians weigh formulation and tablet-handling differences in real-world adherence. Dechra’s promotional framing around partnership, feeling better, and cost-effectiveness suggests the company will compete on both emotional and practical value, not just generic status alone. (equinefacilitydesign.com)